<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01871493</url>
  </required_header>
  <id_info>
    <org_study_id>14833</org_study_id>
    <secondary_id>I6O-FW-BHBA</secondary_id>
    <nct_id>NCT01871493</nct_id>
  </id_info>
  <brief_title>A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Pharmacokinetics of LY2605541 Injection and Insulin Lispro Injection Administered as Mixture or as Individual Components in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate how the body absorbs and removes LY2605541,
      insulin lispro, and a mixture of both from the blood. The study has two parts. Participants
      may enroll in only one part. Each part has four treatment periods in a fixed order. The study
      will last approximately 8 weeks, not including screening. Screening is required within 28
      days prior to the start of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Time to Reach Peak Concentration (tmax) of LY2605541 and Insulin Lispro</measure>
    <time_frame>Pre-dose up to 216 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY2605541 and Insulin Lispro</measure>
    <time_frame>Pre-dose up to 216 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-âˆž) of LY2605541 and Insulin Lispro</measure>
    <time_frame>Pre-dose up to 216 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Glucose Infusion Rate (Rmax)</measure>
    <time_frame>Predose up to 32 hours post clamp procedure in all treatment periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Glucose Infused Over Clamp Duration (Gtot)</measure>
    <time_frame>Predose up to 32 hours post clamp procedure in all treatment periods</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>LY2605541-Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.42 units per kilogram (U/kg) of LY2605541 given once daily (QD) for 1 day, subcutaneously (SQ) in 1 of 4 treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro-Part A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose 0.36 U/kg of insulin lispro given QD for 1 day, SQ in 1 of 4 treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541/Lispro Mix 1-Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 0.54 U/kg of LY2605541 and 0.36 U/kg insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541/Lispro Mix 2-Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 1.42 U/kg of LY2605541 and 0.36 insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro-Part B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.18 U/kg insulin lispro given twice daily (BID) for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541/Lispro Mix-Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.71 U/kg LY2605541 and 0.18 U/kg insulin lispro mixture given BID for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541 QD-Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.54 U/kg of LY2605541 given QD for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541 BID-Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.71 U/kg of LY2605541 given BID for 1 day SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2605541</intervention_name>
    <description>Administered subcutaneous (SQ)</description>
    <arm_group_label>LY2605541-Part A</arm_group_label>
    <arm_group_label>LY2605541/Lispro Mix 1-Part A</arm_group_label>
    <arm_group_label>LY2605541/Lispro Mix 2-Part A</arm_group_label>
    <arm_group_label>LY2605541/Lispro Mix-Part B</arm_group_label>
    <arm_group_label>LY2605541 QD-Part B</arm_group_label>
    <arm_group_label>LY2605541 BID-Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>Administered SQ</description>
    <arm_group_label>Insulin Lispro-Part A</arm_group_label>
    <arm_group_label>LY2605541/Lispro Mix 1-Part A</arm_group_label>
    <arm_group_label>LY2605541/Lispro Mix 2-Part A</arm_group_label>
    <arm_group_label>Insulin Lispro-Part B</arm_group_label>
    <arm_group_label>LY2605541/Lispro Mix-Part B</arm_group_label>
    <other_name>Humalog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are not of child-bearing potential

          -  Have a body mass index (BMI) between 18 and 29.9 kilograms per meter squared (kg/m^2),
             inclusive

          -  Are nonsmokers or have not smoked for at least 2 months prior to entering the study

        Exclusion Criteria:

          -  Have known allergies to insulin or its excipients, or related drugs, or history of
             relevant allergic reactions of any origin

          -  Have a history of first-degree relatives known to have diabetes mellitus

          -  Have used systemic glucocorticoids within 3 months prior to entry into the study

          -  Have donated blood or had a blood loss of 450 milliliter (mL) within 1 month prior to
             study enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <zip>117597</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2013</study_first_submitted>
  <study_first_submitted_qc>June 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2013</study_first_posted>
  <last_update_submitted>October 20, 2014</last_update_submitted>
  <last_update_submitted_qc>October 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

